Forbes J M & Co. LLP Buys 262 Shares of Johnson & Johnson (NYSE:JNJ)

Forbes J M & Co. LLP grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.2% in the 4th quarter, HoldingsChannel.com reports. The fund owned 112,867 shares of the company’s stock after acquiring an additional 262 shares during the period. Johnson & Johnson accounts for about 1.6% of Forbes J M & Co. LLP’s investment portfolio, making the stock its 15th biggest holding. Forbes J M & Co. LLP’s holdings in Johnson & Johnson were worth $16,323,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Archvest Wealth Advisors Inc. bought a new position in Johnson & Johnson in the fourth quarter worth about $210,000. Apollon Wealth Management LLC boosted its holdings in Johnson & Johnson by 20.7% in the fourth quarter. Apollon Wealth Management LLC now owns 105,500 shares of the company’s stock worth $15,257,000 after acquiring an additional 18,082 shares in the last quarter. Vest Financial LLC increased its holdings in shares of Johnson & Johnson by 10.1% during the fourth quarter. Vest Financial LLC now owns 366,147 shares of the company’s stock valued at $52,952,000 after acquiring an additional 33,658 shares in the last quarter. SC&H Financial Advisors Inc. raised its holdings in shares of Johnson & Johnson by 17.0% in the fourth quarter. SC&H Financial Advisors Inc. now owns 1,959 shares of the company’s stock worth $283,000 after buying an additional 285 shares during the last quarter. Finally, Cidel Asset Management Inc. grew its holdings in shares of Johnson & Johnson by 2.8% during the fourth quarter. Cidel Asset Management Inc. now owns 16,338 shares of the company’s stock valued at $2,363,000 after buying an additional 440 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Guggenheim upped their price target on Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Barclays boosted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Finally, Wolfe Research assumed coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 target price for the company. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Trading Up 1.3 %

NYSE JNJ opened at $156.18 on Wednesday. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The firm has a market cap of $376.02 billion, a PE ratio of 23.49, a P/E/G ratio of 2.46 and a beta of 0.52. The firm’s fifty day moving average is $147.40 and its two-hundred day moving average is $156.04. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business earned $2.29 EPS. Analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.18%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.